

Tomoyuki Makino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8404274/publications.pdf>

Version: 2024-02-01

41
papers

405
citations

1039880

9
h-index

839398

18
g-index

42
all docs

42
docs citations

42
times ranked

497
citing authors

#	ARTICLE	IF	CITATIONS
1	Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 1065-1071.	0.5	4
2	Treatment Outcomes in Neuroendocrine Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 2167-2176.	0.5	7
3	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	1.7	5
4	Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 72-80.	1.2	15
5	A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age. <i>Asian Journal of Andrology</i> , 2021, 23, 36.	0.8	4
6	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	1.6	16
7	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. <i>In Vivo</i> , 2021, 35, 2895-2899.	0.6	3
8	Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. <i>In Vivo</i> , 2021, 35, 1703-1709.	0.6	9
9	Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer. <i>In Vivo</i> , 2021, 35, 1247-1252.	0.6	6
10	A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells. <i>Prostate</i> , 2021, 81, 295-306.	1.2	7
11	Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. <i>Biomedicines</i> , 2021, 9, 414.	1.4	12
12	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	1.7	6
13	The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2310-2317.	1.0	2
14	Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 770067.	1.3	5
15	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. <i>Cancers</i> , 2020, 12, 89.	1.7	33
16	Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity. <i>Japanese Journal of Radiology</i> , 2020, 38, 1197-1208.	1.0	4
17	Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" <i>Cancers</i> 2020 12, 89. <i>Cancers</i> , 2020, 12, 354.	1.7	2
18	MP18-06 TUMOR-ASSOCIATED MACROPHAGES INDUCE MIGRATION OF RENAL CELL CARCINOMA CELLS VIA ACTIVATION OF THE CCL20-CCR6 AXIS. <i>Journal of Urology</i> , 2020, 203, e236-e237.	0.2	0

#	ARTICLE	IF	CITATIONS
19	The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4087-4093.	0.5	7
20	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2020, 40, 1141-1146.	0.5	3
21	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. <i>Cancer Science</i> , 2019, 110, 279-288.	1.7	40
22	Metastatic urachal cancer treated effectively with gemcitabine/cisplatin combination chemotherapy and radiotherapy: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 139-142.	0.4	4
23	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. <i>Anticancer Research</i> , 2019, 39, 2607-2614.	0.5	9
24	An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy. <i>Annals of Translational Medicine</i> , 2019, 7, S374-S374.	0.7	1
25	Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. <i>Prostate</i> , 2019, 79, 468-479.	1.2	29
26	Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 477-486.	0.5	6
27	High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma. <i>Anticancer Research</i> , 2019, 39, 375-380.	0.5	5
28	Abstract 1968: Tumor necrosis factor- α upregulation of CCR7 induces prostate cancer cell migration in lymphatic metastasis. , 2019, , .		0
29	Abstract 1968: Tumor necrosis factor- α upregulation of CCR7 induces prostate cancer cell migration in lymphatic metastasis. , 2019, , .		0
30	C α motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. <i>Cancer Science</i> , 2018, 109, 724-731.	1.7	29
31	Tumor necrosis factor- α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. <i>Cancer Science</i> , 2018, 109, 1524-1531.	1.7	72
32	Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. <i>Andrology</i> , 2018, 6, 903-908.	1.9	4
33	Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. <i>In Vivo</i> , 2018, 32, 899-903.	0.6	5
34	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018, 9, 16185-16196.	0.8	26
35	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 2045-2055.	0.5	5
36	Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract. <i>Anticancer Research</i> , 2018, 38, 2241-2245.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy. <i>Prostate International</i> , 2016, 4, 152-155.	1.2	3
38	Mucosa-associated lymphoid tissue lymphoma involving the kidney: a case report and review of the literature. <i>International Cancer Conference Journal</i> , 2016, 5, 82-89.	0.2	4
39	Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. <i>Anticancer Research</i> , 2015, 35, 1723-8.	0.5	5
40	Metastatic Urothelial Carcinoma of the Prepuce and Glans Penis: Suspected Implantation of Non-Muscle-Invasive Bladder Cancer via Urine. <i>Case Reports in Oncology</i> , 2014, 7, 509-512.	0.3	1
41	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	3